· Published by Health Canada · Official notice
This is duplicated text of a letter from Boehringer Ingelheim (Canada) Ltd.
Contact the company for a copy of any references, attachments or enclosures
Notice about Health Canada advisories
March 16, 2012
Dear Health Care Professional,Subject: Updated new recommendations for Pradax® (dabigatran etexilate) regarding renal function assessment, and use in patients with severe valvular disease or prosthetic heart valves.
Boehringer Ingelheim (Canada) Ltd., in consultation with Health Canada, would like to inform you of important new recommendations which have been added to the Product Monograph for Pradax® (dabigatran etexilate).
Pradax® (dabigatran etexilate), an oral anticoagulant, is authorized in Canada for the prevention of stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation is appropriate, or for the prevention of venous thromboembolic events in patients following hip or knee replacement surgery.Footnote 1
The new recommendations for Pradax® are as follows:
Risk of bleeding and renal function assessment:
Based on post-marketing reports of serious bleeding and the use of Pradax® in the elderly and patients at high risk of bleeding or patients with renal impairment, the Product Monograph (PM) has been updated. The updates now include new recommendations to assess renal function in patients being considered for, or already being treated with Pradax® and are as follows:
Health Care Professionals are also reminded that:
Patients with Valvular Disease:
Safety and efficacy of Pradax® have not been studied in patients with hemodynamically significant rheumatic valvular heart disease, especially mitral stenosis, or patients with prosthetic heart valves. There are no data to support that Pradax® provides adequate anticoagulation in patients with prosthetic heart valves, with or without atrial fibrillation. Therefore,the use of Pradax® is not recommended in patients with hemodynamically significant rheumatic valvular heart disease or in patients with prosthetic heart valves.
The full text of the updated Product MonographFootnote 1 can be found at Boehringer Ingelheim (Canada) Ltd web site.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse reactions in patients receiving Pradax® should be reported to Boehringer Ingelheim (Canada) Ltd, or to Health Canada:
Boehringer Ingelheim (Canada) Ltd.,
5180 South Service Rd.
Burlington, ON, L7L 5H4
Tel: 1 (800) 263-5103 Ext. 84603
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffectTM Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
To change your mailing address or fax number, contact the Market Authorization Holder (Industry).
The Pradax® Product MonographFootnote 1 as well as a copy of this letter can be found on the Boehringer Ingelheim (Canada) Ltd., web site.
Sincerely,
original signed by
Mathias Knecht, M.D.
Vice President, Medical and Regulatory Affairs
Boehringer Ingelheim (Canada) Ltd.
Pradax® Product Monograph, dated January 27, 2012